# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.
Full-year 2024 Financial Guidance Confirmed Expected total revenues between €170 million and €190 million, including €160 mi...
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.
Valneva obtains exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate and adds an attractive Phase 2...